Clinical trials in Dordrecht – page 118

1 624 clinical trials in Dordrecht, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Dordrecht at a glance

1 624

clinical trials

Research sites1

Quick filters

1 624 trials in Dordrecht

Open in trial search

Neoplasm malignant

Not recruiting

Study on the Safety and Effects of Vimseltinib for Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

InvestigationalNo placebo

Study on the Safety and Effects of Vimseltinib for Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Vimseltinib
Sponsor:Deciphera Pharmaceuticals Inc.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

Study Comparing Adagrasib and Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Adagrasib
Sponsor:Mirati Therapeutics Inc.

Contact Research Centre

Type 1 diabetes mellitus

Not recruiting

Study on the Safety and Effectiveness of Diamyd and Colecalciferol for Adolescents and Adults with Recently Diagnosed Type 1 Diabetes

Registered drug

Study on the Safety and Effectiveness of Diamyd and Colecalciferol for Adolescents and Adults with Recently Diagnosed Type 1 Diabetes

Registered drug

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Colecalciferol
Sponsor:Diamyd Medical AB

Contact Research Centre

Thrombotic thrombocytopenic purpura

Not recruiting

Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Registered drugNo placebo

Study on Caplacizumab and Immunosuppressive Therapy for Adults with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Caplacizumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan for Patients with Advanced or Metastatic Non-small Cell Lung Cancer with Specific Genetic Changes

InvestigationalNo placebo

Study of Datopotamab Deruxtecan for Patients with Advanced or Metastatic Non-small Cell Lung Cancer with Specific Genetic Changes

InvestigationalNo placebo

The Netherlands

Participants:18–64 years
Substances:Datopotamab Deruxtecan
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Primary immunodeficiency syndrome+2

Not recruiting

Study on the Effect of Human Normal Immunoglobulin on Lung Disease in Patients with Primary Antibody Deficiency

Registered drugNo placebo

Study on the Effect of Human Normal Immunoglobulin on Lung Disease in Patients with Primary Antibody Deficiency

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Human Normal Immunoglobulin
Sponsor:Universitair Medisch Centrum Utrecht

Contact Research Centre

Glycogen storage disease type II

Not recruiting

Study on Long-term Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Adults with Late-onset Pompe Disease

InvestigationalNo placebo

Study on Long-term Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Adults with Late-onset Pompe Disease

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Miglustat
Sponsor:Amicus Therapeutics Inc.

Contact Research Centre

Endometrial cancer stage III+1

Not recruiting

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug

Study on Dostarlimab, Carboplatin, and Paclitaxel for Patients with Recurrent or Advanced Endometrial Cancer

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Tesaro Inc.

Contact Research Centre

Bladder cancer

Not recruiting

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Astrazeneca AB

Contact Research Centre

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study of Lutetium (177Lu) Edotreotide compared to standard treatment in patients with aggressive Grade 2 and Grade 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Registered drugNo placebo

Study of Lutetium (177Lu) Edotreotide compared to standard treatment in patients with aggressive Grade 2 and Grade 3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:ITM Solucin GmbH

Contact Research Centre

Diffuse large B-cell lymphoma+2

Not recruiting

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Celgene Corp.

Contact Research Centre

Glioma

Not recruiting

Study of Vorasidenib for Patients with Residual or Recurrent Grade 2 Glioma with IDH1 or IDH2 Mutation

Investigational

Study of Vorasidenib for Patients with Residual or Recurrent Grade 2 Glioma with IDH1 or IDH2 Mutation

Investigational

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Vorasidenib
Sponsor:Institut De Recherches Internationales Servier IRIS

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Dordrecht

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on Acute Myeloid Leukemia (AML) and various forms of Multiple Myeloma, evaluating novel drug combinations and treatment approaches for patients ineligible for intensive chemotherapy.

Blood Cancer Therapies
Leukemia Treatment
Novel Drug Combinations

Studies aim to improve survival rates and treatment outcomes in previously untreated patients.

02 Cardiovascular Medicine

Research centered on atherosclerotic cardiovascular disease and deep vein thrombosis, investigating new therapeutic approaches and preventive strategies.

Heart Disease Management
Blood Clot Prevention
Cardiac Interventions

Clinical trials focus on improving patient outcomes through innovative treatments and prevention strategies.

03 Endocrine Disorders

Studies examining treatments for thyroid conditions and hormonal disorders, comparing conventional and innovative therapeutic approaches.

Thyroid Disease Management
Hormone Therapy
Quality of Life Improvement

Research aims to enhance treatment efficacy while minimizing side effects.

Back to the Netherlands All countries